Neurocrine Biosciences (NASDAQ:NBIX) PT Lowered to $114.00

Neurocrine Biosciences (NASDAQ:NBIX) had its price target lowered by Mizuho from $116.00 to $114.00 in a research report report published on Friday, Benzinga reports. The firm currently has a neutral rating on the stock.

NBIX has been the subject of a number of other reports. Bank of America upped their target price on shares of Neurocrine Biosciences from $137.00 to $143.00 in a report on Sunday, October 8th. Jefferies Financial Group lifted their target price on shares of Neurocrine Biosciences to $123.00 in a report on Monday, August 21st. BMO Capital Markets cut their price target on shares of Neurocrine Biosciences from $111.00 to $100.00 and set a market perform rating for the company in a report on Friday. Raymond James lifted their price objective on Neurocrine Biosciences from $135.00 to $145.00 and gave the company an outperform rating in a report on Wednesday, November 1st. Finally, SVB Leerink boosted their target price on Neurocrine Biosciences from $125.00 to $135.00 in a research report on Friday, October 6th. Five analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of Moderate Buy and an average target price of $131.46.

Neurocrine Biosciences Stock Performance

Shares of Neurocrine Biosciences stock opened at $107.17 on Friday. The company has a 50-day simple moving average of $112.09 and a two-hundred day simple moving average of $103.38. The company has a market capitalization of $10.53 billion, a PE ratio of 57.62, a P/E/G ratio of 1.01 and a beta of 0.40. Neurocrine Biosciences has a one year low of $89.04 and a one year high of $129.29.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Tuesday, October 31st. The company reported $0.82 EPS for the quarter, missing the consensus estimate of $0.91 by ($0.09). Neurocrine Biosciences had a net margin of 10.71% and a return on equity of 10.54%. The business had revenue of $498.80 million during the quarter, compared to analyst estimates of $479.09 million. During the same period in the previous year, the business posted $0.69 earnings per share. The firm’s revenue for the quarter was up 28.6% on a year-over-year basis. On average, equities analysts predict that Neurocrine Biosciences will post 2.14 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Neurocrine Biosciences news, insider Julie Cooke sold 824 shares of the company’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $110.93, for a total transaction of $91,406.32. Following the completion of the sale, the insider now owns 17,263 shares in the company, valued at approximately $1,914,984.59. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Julie Cooke sold 824 shares of the business’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $110.93, for a total value of $91,406.32. Following the sale, the insider now directly owns 17,263 shares of the company’s stock, valued at approximately $1,914,984.59. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Kevin Charles Gorman sold 9,328 shares of the stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $107.40, for a total transaction of $1,001,827.20. Following the transaction, the chief executive officer now owns 499,754 shares of the company’s stock, valued at $53,673,579.60. The disclosure for this sale can be found here. In the last three months, insiders sold 31,083 shares of company stock valued at $3,400,811. 4.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Neurocrine Biosciences

Hedge funds have recently modified their holdings of the company. Rice Hall James & Associates LLC grew its holdings in Neurocrine Biosciences by 195.5% during the 1st quarter. Rice Hall James & Associates LLC now owns 206,755 shares of the company’s stock worth $19,383,000 after acquiring an additional 136,782 shares during the period. HighTower Advisors LLC grew its stake in Neurocrine Biosciences by 48.8% during the first quarter. HighTower Advisors LLC now owns 5,745 shares of the company’s stock worth $544,000 after purchasing an additional 1,883 shares during the period. PNC Financial Services Group Inc. increased its holdings in Neurocrine Biosciences by 27.7% in the first quarter. PNC Financial Services Group Inc. now owns 3,150 shares of the company’s stock worth $296,000 after purchasing an additional 684 shares in the last quarter. Acadian Asset Management LLC bought a new position in Neurocrine Biosciences during the first quarter worth $27,000. Finally, Dimensional Fund Advisors LP boosted its position in shares of Neurocrine Biosciences by 39.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 417,604 shares of the company’s stock worth $39,148,000 after purchasing an additional 117,422 shares in the last quarter. Institutional investors and hedge funds own 93.54% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.